Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New implant aims to simplify dialysis fistula monitoring

NCT ID NCT04896476

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called EchoMark LP, which is implanted near a surgically created blood vessel connection (fistula) used for dialysis. The device works with a special ultrasound system (EchoSure) to measure blood flow, depth, and diameter of the fistula. The trial involved 20 adults with kidney disease who needed a fistula, and its main goal was to see if the implant is safe and if the measurements can be taken successfully.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EchoMark LP implant and EchoSure diagnostic ultrasound system
What this could lead to
If successful, this device could make it easier and safer to monitor arteriovenous fistulas in dialysis patients, potentially reducing complications.
What could go wrong
This is a very small, early feasibility study with only 20 participants. It is designed to test safety and basic function, not to prove the device improves health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jan 2022

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or non-pregnant, non-breastfeeding females ≥ 18 years of age but \< 85 years of age at the time of informed consent 2. Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures 3. Subject is willing and capable of complying with all required follow-up visits 4. Subject and/or Care Team agree that the distance and transportation resources from the subject's home to the clinic are reasonable for study participation and compliance 5. Subject has an estimated life expectancy \> 18 months 6. Subject is ambulatory (cane or walker are acceptable) 7. Subjects presenting for upper arm autologous arteriovenous fistula creation 8. Vein diameter \> 2.5 mm at the antecubital fossa via imaging 9. Artery diameter \> 3 mm via imaging 10. Subject is not participating in another investigational clinical trial that has not met its primary endpoint. Participation in a post-market registry is acceptable. Exclusion Criteria: 1. Subjects receiving a forearm fistula. 2. Subject has history of Steal Syndrome. 3. Subject who is immunocompromised or immunosuppressed. 4. Subject has had three previous failed AV fistulae for hemodialysis access 5. Subjects expecting to undergo major surgery within 60 days from the EchoMark implantation. 6. Known or suspected active infection on the day of the index procedure. 7. Subjects who had infection(s) in the 30-day window prior to EchoMark placement to reduce the likelihood of partially treated infections that can seed the device and fistula 8. Subjects with diagnosed bleeding disorder, thrombocytopenia (platelet count \<50,000), hypercoagulability, and history of recurrent deep vein thrombosis not related to AV access 9. Subjects with active malignancy 10. Subjects with a history of poor compliance with the dialysis protocol 11. Subjects with a known or suspected allergy to any of the device materials 12. Subjects with an existing fistula or graft 13. Subjects who are pregnant, plan to become pregnant, or are breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arteriovenous fistula are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Michgan Vascular Center

    Flint, Michigan, 48507, United States

  • SKI Vascular Center

    Peoria, Arizona, 85381, United States

  • Surgical Specialist of Charlotte

    Charlotte, North Carolina, 28207, United States

  • Trinity Research Group

    Dothan, Alabama, 36301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.